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Enzymatic fluorometric assay 
A B S T R A C T   
Phosphatidylcholine (PC), phosphatidylethanolamine (PE) and sphingomyelin (SM) are important surface 
components of plasma lipoproteins, including very-low-density lipoproteins (VLDL), low-density lipoproteins 
(LDL) and high-density lipoproteins (HDL). However, the pathophysiological roles of PC, PE and SM in lipo-
proteins have not been well characterized owing to the difficulties in quantifying phospholipid classes in lipo-
proteins. In this study, we assessed the precision and accuracy of the enzymatic fluorometric assays for 
measuring PC, PE and SM in VLDL, LDL and HDL, which were isolated from human plasma by ultracentrifu-
gation. The within-run coefficients of variation (CV) for the measurements of PC, PE and SM in lipoproteins were 
1.5–2.8 %, 1.1–2.4 % and 0.9–2.3 %, respectively, whereas the between-run CVs for the PC, PE and SM assays 
were 2.7–4.7 %, 2.1–4.5 % and 1.6–3.3 %, respectively. Excellent linearity and almost complete recovery were 
achieved for all assays measuring PC, PE and SM in VLDL, LDL and HDL. Our preliminary results using these 
enzymatic fluorometric assays suggested that the phospholipid compositions were different among VLDL, LDL 
and HDL. In conclusion, we established high-throughput enzymatic fluorometric assays to quantify PC, PE and 
SM in human plasma VLDL, LDL and HDL, which will be useful for further investigation of pathophysiological 
roles of phospholipids in lipoproteins.   
1. Introduction 
Phospholipids are essential components of plasma lipoproteins 
including high-density lipoproteins (HDL), low-density lipoproteins 
(LDL), very-low-density lipoproteins (VLDL) and chylomicrons. Phos-
pholipids, together with cholesterol, are necessary to constitute a 
lipoprotein-surface monolayer, which envelops a hydrophobic core 
consisting of triglyceride and cholesteryl esters (Jonas and Phillips, 
2008; Morita, 2016). Phosphatidylcholine (PC) is the primary phos-
pholipid component of lipoproteins, and sphingomyelin (SM) is the 
second most abundant phospholipid in lipoproteins (Jonas and Phillips, 
2008; Morita, 2016). The lipoprotein-surface phospholipids play key 
roles in the lipoprotein metabolism by controlling the binding of apo-
lipoproteins and enzymes to lipoproteins. For example, apolipoprotein E 
bound on the lipoprotein remnant surface increases the uptake of 
remnants into hepatocytes via the LDL receptor, LDL receptor-related 
protein and heparan sulfate proteoglycans (Mahley and Huang, 2007; 
Morita, 2016; Morita et al., 2003; Morita et al., 2011; Sakurai et al., 
2005; Wakita et al., 2015). Apolipoprotein C-II is essential for the acti-
vation of lipoprotein lipase at the surface of VLDL, whereas apolipo-
protein C-III strongly inhibits the lipoprotein lipase-mediated lipolysis 
and promotes hepatic VLDL assembly and secretion (Morita, 2016; 
Wolska et al., 2017; Yamamoto et al., 2003; Zheng, 2014). 
It is well known that high levels of LDL-cholesterol and low levels of 
HDL-cholesterol increase the risk of coronary artery disease (Morita, 
2016). In addition, it has been reported that plasma SM levels and 
SM/(PC + SM) ratios are positively and independently correlated with 
coronary artery disease (Jiang et al., 2000). PC, SM and phosphatidyl-
ethanolamine (PE) are incorporated into VLDL particles in hepatocytes 
and then secreted into the circulation. As SM, but not PC, is resistant to 
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hydrolysis by lipoprotein lipase, hepatic lipase or lecithin:cholesterol 
acyltransferase, the SM/PC ratio in LDL is higher than that in VLDL 
(Morita, 2016). We have previously demonstrated that SM suppresses 
the binding of apolipoprotein E to the particle surface and the apoli-
poprotein E-mediated cellular uptake of the particles (Morita et al., 
2003). Sphingomyelinase (SMase) hydrolyzes SM to ceramide and 
phosphorylcholine (Morita et al., 2004). The treatment of LDL with 
SMase leads to the aggregation and fusion of the particles (Schissel et al., 
1996). We have also observed ceramide-enriched microdomains in the 
SMase-treated particles by confocal microscopy (Morita et al., 2005). 
Alteration of LDL by SMase promotes the internalization of LDL into 
macrophages and foam cell formation (Marathe et al., 2000). Thus, the 
generation of ceramide from SM contained in LDL is considered to be an 
important step in atherogenesis. Dashti et al. have observed abundant PE 
in VLDL by high-performance thin layer chromatography analysis 
(Dashti et al., 2011). During lipolysis of VLDL, PE may be more prefer-
ably hydrolyzed than PC (Zhao et al., 2009). The clearance of VLDL with 
a high ratio of PE/PC is promoted (Zhao et al., 2009). However, little is 
known about whether alteration of the amount of PC, PE and SM in each 
lipoprotein fraction, VLDL, LDL or HDL, correlates with the onset or 
progression of diseases. 
Enzymatic assays are simple, rapid and high-throughput. The spe-
cific enzymatic measurements of PC, PE and SM in serum or plasma have 
been performed and validated (Hidaka et al., 2008; Hojjati and Jiang, 
2006; Hokazono et al., 2011). On the other hand, the accuracy of 
enzymatic measurements of PC, PE and SM has not been confirmed for 
isolated lipoprotein fractions. We have developed fluorometric assays 
for all major phospholipid classes, including PC, PE and SM, using 
combinations of specific enzymes and 10-acetyl-3,7-dihydroxyphenoxa-
zine (Amplex Red), which enable high-throughput and high-sensitive 
quantification in pico-molar ranges (Morita et al., 2012a; Morita et al., 
2012b; Morita et al., 2010; Morita and Terada, 2015; Morita et al., 2020; 
Morita et al., 2009; Tsuji et al., 2019). Recently, we have revealed that 
the phospholipid class compositions of HepG2 cells and their intracel-
lular organelles are altered during cell growth using these enzymatic 
fluorometric assays (Tsuji et al., 2021). In the present study, we applied 
these enzymatic fluorometric assays to quantify PC, PE and SM in human 
plasma VLDL, LDL and HDL, and assessed their precision and accuracy. 
2. Material and methods 
2.1. Materials 
Triton X-100 was obtained from Roche Diagnostics (Mannheim, 
Germany). Amplex Red Reagent and Amplex Red Stop Regent were 
Fig. 1. Size distribution of lipoprotein particles. Human plasma VLDL (a), LDL (b) and HDL (c) fractions were isolated by the ultracentrifugation method. The 
volume-weighted distribution of particle sizes was assessed by dynamic light scattering. The volume-weighted mean diameters of VLDL, LDL and HDL were 39.1, 
19.6 and 11.7 nm, respectively. 
Table 1 
Within-run reproducibility of measurements of PC, PE and SM in plasma VLDL, 
LDL and HDL.  








PC in VLDL  PC in LDL  PC in HDL  
A-1 162.4 ± 2.6 1.6 1001.6 ± 20.0 2.0 503.5 ± 14.1 2.8 
B-1 112.1 ± 2.1 1.9 546.7 ± 8.4 1.5 411.8 ± 7.5 1.8 
C-1 249.8 ± 5.4 2.1 784.2 ± 20.2 2.6 443.3 ± 7.2 1.6  
PE in VLDL  PE in LDL  PE in HDL  
A-2 5.2 ± 0.1 2.4 46.6 ± 0.6 1.3 41.6 ± 0.8 2.0 
B-2 12.1 ± 0.2 1.6 34.0 ± 0.5 1.4 24.6 ± 0.4 1.7 
C-2 16.4 ± 0.2 1.1 25.9 ± 0.4 1.6 15.9 ± 2.2 1.6  
SM in VLDL  SM in LDL  SM in HDL  
A-3 20.8 ± 0.5 2.2 294.0 ± 5.8 2.0 85.0 ± 1.1 1.3 
B-3 14.0 ± 0.3 2.0 165.5 ± 2.6 1.5 69.5 ± 1.0 1.4 
C-3 18.9 ± 0.2 0.9 225.5 ± 5.2 2.3 77.2 ± 0.9 1.2 
Samples for PC, PE and SM measurements were isolated from different plasma 
samples. Ten aliquots of each sample were simultaneously measured by the 
enzymatic fluorometric assays (n = 10). 
Table 2 
Between-run reproducibility of measurements of PC, PE and SM in plasma VLDL, 
LDL and HDL.  








PC in VLDL  PC in LDL  PC in HDL  
A-1 155.2 ± 6.1 3.9 957.3 ± 45.4 4.7 506.3 ± 17.3 3.4 
B-1 110.9 ± 4.5 4.0 556.2 ± 18.8 3.4 411.8 ± 12.6 3.1 
C-1 241.0 ± 6.9 2.8 800.4 ± 16.2 2.0 435.5 ± 11.6 2.7  
PE in VLDL  PE in LDL  PE in HDL  
A-2 5.9 ± 0.3 4.3 50.9 ± 2.1 4.0 47.6 ± 1.3 2.8 
B-2 13.2 ± 0.3 2.2 36.7 ± 0.8 2.1 26.4 ± 0.8 3.1 
C-2 17.8 ± 0.8 4.4 27.5 ± 1.0 3.8 17.1 ± 0.8 4.5  
SM in VLDL  SM in LDL  SM in HDL  
A-3 20.2 ± 0.5 2.2 299.2 ± 7.9 2.6 82.6 ± 2.7 3.3 
B-3 15.1 ± 0.5 3.2 181.9 ± 5.4 3.0 72.4 ± 1.1 1.6 
C-3 20.4 ± 0.6 2.7 247.7 ± 6.7 2.7 81.1 ± 2.5 3.1 
Samples for PC, PE and SM measurements were isolated from different plasma 
samples. Each sample was measured in duplicate once daily for 10 days by the 
enzymatic fluorometric assays with the same reagent lots (n = 10). To avoid 
repeated freeze-thaw cycles, the sample solution was separated into ten sample 
tubes and frozen at − 20 ◦C immediately after preparation. 
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purchased from Thermo Fisher Scientific (Waltham, MA, USA). 1-Palmi-
toyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2- 
oleoyl-sn-glycero-3-phosphoethanolamine (POPE) and SM from 
chicken egg (egg SM) were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA). Phospholipase D from Streptomyces chromofuscus 
and tyramine oxidase from Arthrobacter sp. were obtained from Asahi 
Kasei Pharma (Tokyo, Japan). Peroxidase from horseradish roots was 
purchased from Oriental Yeast (Tokyo, Japan). All other chemicals used 
were of the highest reagent grade. 
2.2. Subjects and blood sampling 
Blood samples from healthy volunteers (three males aged 32–49 
years, subjects A, B and C) after 12-h overnight fasting were collected in 
sterilized vacuum tubes containing EDTA-2Na (Venoject II, Terumo, 
Tokyo, Japan) using 23-gauge needles. The collected blood samples 
Fig. 2. Linearity of measurements of PC, PE and SM in VLDL, LDL and HDL. Samples for PC, PE and SM measurements were isolated from different plasma samples 
collected from three different subjects (subject A, closed circles; subject B, open circles; subject C, open squares). The lipid extracts from VLDL, LDL and HDL were 
sequentially diluted in 1% Triton X-100. PC concentrations in VLDL (a), LDL (b) and HDL (c) (sample A-1, B-1 and C-1), PE concentrations in VLDL (d), LDL (e) and 
HDL (f) (sample A-2, B-2 and C-2), and SM concentrations in VLDL (g), LDL (h) and HDL (i) (sample A-3, B-3 and C-3) were measured by the enzymatic fluorometric 
assays. (a) Sample A-1, r = 0.9999; sample B-1, r = 0.9991; sample C-1, r = 0.9997. (b) Sample A-1, r = 0.9988; sample B-1, r = 0.9995; sample C-1, r = 0.9982. (c) 
Sample A-1, r = 0.9996; sample B-1, r = 1.000; sample C-1, r = 0.9997. (d) Sample A-2, r = 0.9995; sample B-2, r = 0.9989; sample C-2, r = 0.9996. (e) Sample A-2, r 
= 0.9994; sample B-2, r = 0.9985; sample C-2, r = 0.9986. (f) Sample A-2, r = 0.9995; sample B-2, r = 0.9997; sample C-2, r = 0.9995. (g) Sample A-3, r = 0.9998; 
sample B-3, r = 0.9996; sample C-3, r = 0.9999. (h) Sample A-3, r = 0.9997; sample B-3, r = 1.000; sample C-3, r = 0.9999. (i) Sample A-3, r = 0.9998; sample B-3, r 
= 0.9995; sample C-3, r = 0.9997. 
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were placed on ice and centrifuged (1200 g, 10 min, 4 ◦C) within 30 min 
of collection to obtain blood plasma samples. This study was approved 
by the ethics committee of Shiga University of Medical Science 
(R2019− 242), and all subjects provided written informed consent. Our 
study was conducted in accordance with the Declaration of Helsinki. 
2.3. Plasma lipoprotein isolation 
Immediately after plasma collection, VLDL, LDL and HDL fractions 
were isolated by ultracentrifugation using a himac CS120FNX ultra-
centrifuge with a fixed angle rotor S110AT (Eppendorf Himac Tech-
nologies, Hitachinaka, Japan) according to the previously described 
method with slight modification (Chunta et al., 2016; Chunta et al., 
2018). Briefly, 1.0 mL of solution A (0.195 M NaCl; density 1.006 g/mL) 
was layered on the top of 2.0 mL of plasma in a 3.4-mL polycarbonate 
tube. After centrifugation (650,000 g, 90 min, 4 ◦C), the VLDL fraction 
(1.0 mL) was collected from the top layer. Next, 1.0 mL of solution B 
(0.195 M NaCl and 2.44 M NaBr; density 1.182 g/mL) was added to the 
bottom layer containing LDL, HDL and other plasma proteins. After 
mixing and centrifugation (650,000 g, 130 min, 4 ◦C), the LDL fraction 
(1.0 mL) was collected from the top layer. Then, 1.0 mL of solution C 
(0.195 M NaCl and 7.65 M NaBr; density 1.478 g/mL) was added to the 
bottom layer and mixed. Centrifugation (650,000 g, 210 min, 4 ◦C) 
yielded the HDL fraction in the top layer (0.4 mL). Particle sizes of the 
isolated lipoproteins were measured by dynamic light scattering using 
Litesizer 100 (Anton Paar, Graz, Austria). 
2.4. Phospholipid extraction 
Phospholipids were extracted from the isolated plasma lipoprotein 
fractions by the method of Folch (Folch et al., 1957; Tsuji et al., 2019; 
Wakelam et al., 2007). In brief, sample solution/chloroform/methanol 
(3:8:4) was vortexed, incubated overnight at 4 ◦C and centrifuged to 
complete phase separation. After removal of the upper aqueous phase 
and the interfacial material, the recovered lower organic phase was 
washed with H2O, and the aqueous phase was removed again. The 
organic solvent was evaporated from the lower phase. The evaporated 
sample was dissolved by adding 1% Triton X-100 (250 μL) and filtered 
through Durapore hydrophilic polyvinylidene fluoride membrane 
(0.45-μm pore size, Ultrafree-MC, Merck-Millipore, Billerica, MA, USA). 
We have confirmed that PC, PE and SM were almost completely recov-
ered by the Folch method (Tsuji et al., 2021). 
2.5. Measurement of phospholipid contents in human plasma lipoproteins 
The PC and SM contents in the extracts of lipoproteins were quan-
tified by enzymatic fluorometric methods (Morita et al., 2012a; Morita 
et al., 2010). Before the enzymatic fluorometric assay, a sample con-
taining a high concentration of PC, PE or SM was diluted to be within the 
measurable range. POPC or egg SM dissolved in 1% Triton X-100 solu-
tion was used as the standard for measuring PC and SM, respectively. For 
PE measurement, we slightly modified the enzymatic fluorometric 
method that we have previously reported (Morita et al., 2010). Reagent 
Table 3 
Recovery of PC added to lipid extract from plasma VLDL, LDL and HDL.  
Sample Added PC Measured PC Expected PC Recovery  
(μM) (μM) (μM) (%) 
VLDL     
A 0 53.5 − −
20 73.1 73.5 99.5  
40 93.1 93.5 99.6  
60 110.5 113.5 97.4 
B 0 43.3 − −
20 62.8 63.3 99.2  
40 83.5 83.3 100.2  
60 102.5 103.3 99.2 
C 0 47.9 − −
20 67.5 67.9 99.4  
40 89.5 87.9 101.8  
60 108.0 107.9 100.1 
LDL     
A 0 37.7 − −
20 57.4 57.7 99.5  
40 78.5 77.7 101.0  
60 97.0 97.7 99.3 
B 0 20.4 − −
20 39.0 40.4 96.5  
40 61.0 60.4 101.0  
60 82.3 80.4 102.4 
C 0 29.8 − −
20 47.4 49.8 95.2  
40 69.2 69.8 99.1  
60 87.4 89.8 97.3 
HDL     
A 0 26.3 − −
20 46.9 46.3 101.3  
40 65.8 66.3 99.2  
60 85.3 86.3 98.8 
B 0 16.7 − −
20 35.1 36.7 95.6  
40 55.9 56.7 98.6  
60 77.2 76.7 100.7 
C 0 17.2 − −
20 36.1 37.2 97.0  
40 56.3 57.2 98.4  
60 76.5 77.2 99.1 
POPC standard solution was added to the lipid extract. The concentration of PC 
was measured by the enzymatic fluorometric assay. 
Table 4 
Recovery of PE added to lipid extract from plasma VLDL, LDL and HDL.  
Sample Added PE Measured PE Expected PE Recovery  
(μM) (μM) (μM) (%) 
VLDL     
A 0 10.8 − −
20 31.0 30.8 100.6  
40 52.3 50.8 103.0  
60 72.1 70.8 101.8 
B 0 23.0 − −
20 43.2 43.0 100.5  
40 64.5 63.0 102.4  
60 84.3 83.0 101.6 
C 0 32.1 − −
20 51.6 52.1 99.0  
40 72.0 72.1 99.9  
60 90.2 92.1 97.9 
LDL     
A 0 40.4 − −
20 60.1 60.4 99.5  
40 79.4 80.4 98.8  
60 99.0 100.4 98.6 
B 0 29.8 − −
20 49.1 49.8 98.6  
40 69.5 69.8 99.6  
60 91.9 89.8 102.3 
C 0 22.6 − −
20 41.3 42.6 96.9  
40 62.5 62.6 99.8  
60 81.6 82.6 98.8 
HDL     
A 0 34.4 − −
20 54.6 54.4 100.4  
40 73.4 74.4 98.7  
60 94.5 94.4 100.1 
B 0 18.4 − −
20 37.6 38.4 97.9  
40 58.7 58.4 100.5  
60 79.1 78.4 100.9 
C 0 12.9 − −
20 32.8 32.9 99.7  
40 54.0 52.9 102.1  
60 74.2 72.9 101.8 
POPE standard solution was added to the lipid extract. The concentration of PE 
was measured by the enzymatic fluorometric assay. 
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E1 (15 μL) containing 320 U/mL phospholipase D, 2.4 mM CaCl2, 50 mM 
NaCl and 50 mM Tris− HCl (pH 7.4) was added to the sample (15 μL) and 
incubated at 37 ◦C for 2 h. The reaction mixture was incubated at 96 ◦C 
for 3 min and centrifuged at 7,200 g for 5 min to remove the denatured 
enzyme. The supernatant (20 μL) was mixed with Regent E2 (80 μL) 
containing 12.5 U/mL tyramine oxidase, 3.125 U/mL peroxidase, 187.5 
μM Amplex Red, 0.125 % Triton X-100, 50 mM NaCl and 50 mM 
Tris− HCl (pH 7.4). After a 30-min incubation at 37 ◦C, Amplex Red Stop 
Reagent (20 μL) was added. Fluorescence intensity was measured at 
544/590 nm (excitation/emission) by a SpectraMax iD3 multi-mode 
microplate reader (Molecular Devices, San Jose, CA, USA). POPE dis-
solved in 1% Triton X-100 solution was used as the standard for 
measuring PE. 
3. Results and discussion 
3.1. Particle sizes of isolated lipoproteins 
We isolated human plasma lipoproteins, VLDL, LDL and HDL, by 
differential ultracentrifugation as described previously (Carlson, 1973; 
Chunta et al., 2016; Chunta et al., 2018). Non-denaturing poly-
acrylamide gradient gel electrophoresis and gel filtration chromatog-
raphy have been widely used to characterize the isolated lipoprotein 
fractions (Gambert et al., 1990; Innis-Whitehouse et al., 1998). In 
addition, the dynamic light scattering technique has been established to 
determine the lipoprotein particle sizes, and the lipoprotein sizes 
determined by dynamic light scattering have been strongly correlated 
with those determined by non-denaturing polyacrylamide gradient gel 
electrophoresis and have been consistent with the gel filtration elution 
profiles (Alexandre et al., 2015; Chandra et al., 2016; Lima and Mar-
anhao, 2004; O’Neal et al., 1998; Sakurai et al., 2010). In this study, to 
characterize the isolated lipoprotein fractions, we determined the size 
distribution of lipoprotein particles by dynamic light scattering mea-
surement (Fig. 1a-c). The volume-weighted mean diameters of VLDL, 
LDL and HDL were 39.1, 19.6 and 11.7 nm, respectively, suggesting that 
the lipoprotein fractions were sufficiently isolated. Because it is difficult 
to strictly separate the particles at certain diameters by centrifugation 
procedures, the size distributions showed partial overlaps between li-
poprotein fractions. 
3.2. Assay reproducibility 
We have previously established enzymatic fluorometric assays for 
quantifying PC, PE and SM (Morita et al., 2012b; Morita et al., 2010). To 
evaluate the reproducibility of the assays for PC, PE and SM in lipo-
proteins, the within-run and between-run precision was assessed. VLDL, 
LDL and HDL samples from three different human plasma samples were 
prepared to assess the within-run and between-run coefficients of vari-
ation (CV, n = 10). To determine the within-run CVs, each sample was 
measured in 10 replicates per run. By the enzymatic fluorometric assay, 
the PC contents in VLDL, LDL and HDL were 112–250, 547–1002 and 
412− 504 nmol/mL plasma, respectively (Table 1). The within-run CVs 
of the PC measurements were 1.6–2.1 % for VLDL, 1.5–2.6 % for LDL 
and 1.6–2.8 % for HDL. The PE contents in VLDL, LDL and HDL were 
5–16, 26–47 and 16− 42 nmol/mL plasma, respectively. The within-run 
CVs of the PE measurements for VLDL, LDL and HDL were 1.1–2.4 %, 
1.3–1.6 % and 1.6–2.0 %, respectively. The SM contents in VLDL, LDL 
and HDL were 14–21, 166–294 and 70− 85 nmol/mL plasma, respec-
tively. The within-run CVs of the SM assays for VLDL, LDL and HDL were 
0.9–2.2 %, 1.5–2.3 % and 1.2–1.4 %, respectively. To determine the 
between-run CVs, each sample was assayed in duplicate once daily for 
10 days using the enzymatic fluorometric quantification with the same 
reagent lots. As depicted in Table 2, the between-run CVs of the PC 
measurements were 2.8–4.0 % for VLDL, 2.0–4.7 % for LDL and 2.7–3.4 
% for HDL. By the PE enzymatic assay, the between-run CVs for VLDL, 
LDL and HDL were 2.2–4.4 %, 2.1–4.0 % and 2.8–4.5 %, respectively. 
The between-run CVs of the SM assays for VLDL, LDL and HDL were 
2.2–3.2 %, 2.6–3.0 % and 1.6–3.3 %, respectively. The between-run CVs 
of the enzymatic fluorometric assays were relatively high compared 
with the corresponding within-run CVs. The contents of PC, PE and SM 
in lipoproteins tended to slightly decrease from day 1 to day 10, 
although, to avoid repeated freeze-thaw cycles, the sample solution was 
separated into ten sample tubes and frozen at − 20 ◦C immediately after 
preparation. Therefore, we recommend the measurements be performed 
on the day of sample preparation. 
3.3. Assay linearity 
We have previously reported that, for the enzymatic fluorometric 
assays, the detection limits are 1 μM PC, 1 μM PE and 0.5 μM SM, and the 
upper limits are 150 μM PC, 250 μM PE and 100 μM SM (Morita et al., 
2012b; Morita et al., 2010). Next, we investigated the linearity of the 
assays for PC, PE and SM in VLDL, LDL and HDL. The VLDL, LDL, and 
HDL lipid extracts from different human plasma samples were sequen-
tially diluted in 1% Triton X-100 solution within the measurable ranges 
(1–150 μM PC, 1–250 μM PE and 1–100 μM SM). As shown in Fig. 2a-i, 
well-fitted regression lines were produced. The PC assays for VLDL, LDL 
and HDL demonstrated good linearity to 117.3 μM (r > 0.999), 123.6 μM 
(r > 0.998) and 126.4 μM (r > 0.999), respectively (Fig. 2a-c). The PE 
assays also provided good linearity ranges of 0–108.1 μM in VLDL (r >
0.998), 0–158.0 μM in LDL (r > 0.998) and 0–148.7 μM in HDL (r >
0.999) (Fig. 2d-f). In the SM assays, excellent linearity ranges of 0–68.6 
Table 5 
Recovery of SM added to lipid extract from plasma VLDL, LDL and HDL.  
Sample Added SM Measured SM Expected Recovery  
(μM) (μM) (μM) (%) 
VLDL     
A 0 19.8 − −
20 39.4 39.8 99.0  
40 60.3 59.8 100.8  
60 80.6 79.8 101.0 
B 0 27.1 − −
20 45.8 47.1 97.2  
40 68.6 67.1 102.2  
60 87.1 87.1 100.0 
C 0 41.0 − −
20 61.0 61.0 100.0  
40 80.4 81.0 99.3  
60 99.7 101.0 98.7 
LDL     
A 0 22.6 − −
20 41.5 42.6 97.4  
40 63.0 62.6 100.6  
60 83.8 82.6 101.5 
B 0 15.4 − −
20 35.2 35.4 99.4  
40 56.5 55.4 102.0  
60 77.1 75.4 102.3 
C 0 16.8 − −
20 36.3 36.8 98.6  
40 57.8 56.8 101.8  
60 75.2 76.8 97.9 
HDL     
A 0 21.7 − −
20 40.5 41.7 97.1  
40 61.7 61.7 100.0  
60 82.7 81.7 101.2 
B 0 13.7 − −
20 33.4 33.7 99.1  
40 54.5 53.7 101.5  
60 74.8 73.7 101.5 
C 0 15.4 − −
20 35.7 35.4 100.8  
40 56.7 55.4 102.3  
60 76.1 75.4 100.9 
Egg SM standard solution was added to the lipid extract. The concentration of 
SM was measured by the enzymatic fluorometric assay. 
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μM in VLDL (r > 0.999), 0–94.6 μM in LDL (r > 0.999) and 0–75.5 μM in 
HDL (r > 0.999) were obtained Fig. 2g-h). Hence, an appropriate sample 
dilution is required for the phospholipid measurements when the sample 
contains higher concentrations of phospholipids than the upper limits. 
3.4. Assay recovery 
We assessed the accuracy of these assays by recovery studies. The 
method of Folch is one of the most widely used procedures to extract 
lipids (Folch et al., 1957). We have previously demonstrated that PC, PE 
and SM are almost completely recovered by the Folch extraction method 
(Tsuji et al., 2021). After the Folch method, the recovery rates of PC, PE 
and SM are 97.6 %, 99.5 % and 97.4 %, respectively (Tsuji et al., 2021). 
In this study, to confirm the recovery of PC, PE and SM assays, the 
known concentrations of standard solutions (0, 40, 80 and 120 μM) were 
added to the lipoprotein lipid extracts (1:1 ratio by volume). The VLDL, 
LDL and HDL samples from three different plasma samples were tested. 
The recovery of PC added to the VLDL, LDL and HDL lipid extracts at 
concentrations of 20− 60 μM was 97.4–101.8 %, 95.2–102.4 % and 
95.6–101.3 %, respectively (Table 3). The recovery of PE added to the 
VLDL, LDL, and HDL lipid extracts was 97.9–103.0 %, 96.9-102.3 % and 
97.9–102.1 %, respectively (Table 4), and that of SM added to the VLDL, 
LDL, and HDL lipid extracts was 97.2–102.2 %, 97.4–102.3 % and 
97.1–102.3 % (Table 5). Therefore, in the PC, PE and SM assays, there 
was no interference of hydrophobic compounds extracted from human 
plasma lipoproteins. 
3.5. Phospholipid composition in human plasma lipoproteins 
By using the enzymatic fluorometric assays, we determined the 
concentrations of PC, PE and SM in VLDL, LDL and HDL isolated from 
the plasma samples collected from three different subjects (Fig. 3). The 
lipoprotein phospholipid concentration was normalized with the vol-
ume of plasma (nmol/mL plasma), but not with the protein concentra-
tion, because the protein composition and concentration in each 
lipoprotein fraction may differ between individuals. In all samples, the 
concentrations of PC, PE and SM were the highest in LDL (823.4 ±
135.5, 32.9 ± 7.8 and 243.4 ± 37.0 nmol/mL plasma, mean ± S.E., n =
3, respectively), followed in descending order by HDL (481.5 ± 30.8, 
24.9 ± 4.0 and 78.5 ± 2.7 nmol/mL plasma, respectively) and VLDL 
(181.6 ± 40.2, 16.2 ± 2.5 and 19.3 ± 1.6 nmol/mL plasma, respectively) 
(Fig. 3a-c). However, we caution that the lipoprotein phospholipid 
concentration per plasma volume may be affected by the isolation rate of 
the lipoprotein subclass from plasma, which is difficult to determine. In 
addition to the lipoprotein phospholipid concentration (nmol/mL 
plasma), we determined the relative amount of each phospholipid, PE/ 
PC, SM/PC or PE/SM, in each lipoprotein fraction, which appears to be 
largely independent of the lipoprotein isolation rate. As shown in Fig. 3d 
and e, the SM/PC ratio in LDL (0.297 ± 0.005, mean ± S.E., n = 3) was 
higher than that in VLDL (0.113 ± 0.015), whereas the PE/PC ratio was 
lower in LDL (0.039 ± 0.003) than in VLDL (0.092 ± 0.009). In HDL, the 
ratios of PE/PC and SM/PC were 0.051 ± 0.005 and 0.164 ± 0.006, 
respectively (Fig. 3d and e). The PE/SM ratio was in the order VLDL 
(0.827 ± 0.062) > HDL (0.315 ± 0.044) > LDL (0.132 ± 0.012) (Fig. 3f). 
Jiang et al. have reported that the plasma SM levels and SM/(PC +
SM) ratios are higher in patients with coronary artery disease than in 
control subjects (Jiang et al., 2000). Thus, plasma SM levels and SM/(PC 
+ SM) ratios have been suggested to be an independent risk factor of 
coronary artery disease (Jiang et al., 2000). In the arterial wall, SMase 
hydrolyzes SM to ceramide in LDL and enhances the uptake of LDL by 
macrophages, which leads to the formation of foam cells (Morita, 2016). 
SM on the particle surface reduces lipolysis by lipoprotein lipase and the 
hepatocyte uptake mediated by apolipoprotein E, which may delay the 
clearance of VLDL from circulation (Arimoto et al., 1998; Morita et al., 
2003; Saito et al., 2000). Enrichment of HDL with SM suppresses the 
cholesterol esterification mediated by lecithin:cholesterol acyltransfer-
ase (Subbaiah and Liu, 1993). We therefore consider it important to 
quantify PC, PE and SM in each lipoprotein fraction. 
In mouse plasma VLDL, the amount of PC is approximately 30-fold 
larger than that of PE (PE/PC ≈ 0.03) (Zhao et al., 2009). After the 
Fig. 3. Phospholipid composition in human plasma VLDL, LDL and HDL. VLDL, LDL and HDL were isolated from plasma collected from three different subjects 
(subject A, white bars; subject B, black bars; subject C, gray bars) by the ultracentrifugation method. The concentrations of PC (a), PE (b) and SM (c) in VLDL, LDL 
and HDL were measured by the enzymatic fluorometric assays, and the ratios of PE/PC (d), SM/PC (e) and PE/SM (f) were calculated. 
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injection of the lipase inhibitor Poloxamer 407, the PE/PC ratio in VLDL 
increases to approximately 0.08, suggesting that the lipases preferen-
tially hydrolyze PE relative to PC (Zhao et al., 2009). The SM/PC ratio 
increases during the conversion from VLDL to LDL, which may be due to 
the resistance of SM against lipoprotein lipase and hepatic lipase and 
possibly to the slow movement of SM between lipoprotein particles 
(Myher et al., 1989; Subbaiah and Liu, 1993). In humans, the PE/PC 
ratios have been reported to be 0.06 in VLDL, 0.03− 0.04 in LDL, 
0.03− 0.06 in HDL (Dashti et al., 2011; Subbaiah et al., 1989; Subbaiah 
and Liu, 1993). The previously reported ratios of SM/PC in human li-
poproteins are 0.09− 0.23 in VLDL, 0.21− 0.48 in LDL and 0.08− 0.38 in 
HDL (Dashti et al., 2011; Schissel et al., 1998; Subbaiah et al., 1989; 
Subbaiah and Liu, 1993; Windler et al., 1986; Yang and Subbaiah, 
2015). These values have been obtained from small sample size studies 
(n = 1–14) by the conventional methods using thin-layer chromatog-
raphy, which are less sensitive than the enzymatic fluorometric assays. 
The SM/PC ratio in LDL (~0.3) obtained in this study is relatively low 
compared with the ratios in previous reports, which may be partly 
caused by differences in the quantification methods. To establish the 
standard values and to detect abnormalities in the lipoprotein meta-
bolism, we need to measure PC, PE and SM in many lipoprotein samples 
using the enzymatic fluorometric assays. 
4. Conclusion 
In conclusion, we optimized and validated the enzymatic fluoro-
metric assays for the quantification of PC, PE and SM in VLDL, LDL and 
HDL. These enzymatic fluorometric assays enable more precise and ac-
curate quantifications of phospholipid classes in lipoproteins. Although 
the physiological and pathological roles of PC, PE and SM in lipoproteins 
remain largely unknown, these enzymatic fluorometric assays will be 
helpful in clarifying the functions of PC, PE and SM in lipoprotein 
metabolism and in exploring their relationships with diseases including 
atherosclerosis. 
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